Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the H eart F ailure A ssociation ( HFA ), the E uropean A ssociation of C ardiovascular I maging ( EACVI ) and the Cardio‐Oncology C ouncil of the E uropean S ociety of C ardiology ( ESC )

Archive ouverte

Čelutkienė, Jelena | Pudil, Radek | López‐fernández, Teresa | Grapsa, Julia | Nihoyannopoulos, Petros | Bergler‐klein, Jutta | Cohen‐solal, Alain | Farmakis, Dimitrios | Tocchetti, Carlo Gabriele | Haehling, Stephan | Barberis, Vassilis | Flachskampf, Frank | Čeponienė, Indrė | Haegler‐laube, Eva | Suter, Thomas | Lapinskas, Tomas | Prasad, Sanjay | Boer, Rudolf | Wechalekar, Kshama | Anker, Markus | Iakobishvili, Zaza | Bucciarelli‐ducci, Chiara | Schulz‐menger, Jeanette | Cosyns, Bernard | Gaemperli, Oliver | Belenkov, Yury | Hulot, Jean‐sébastien | Galderisi, Maurizio | Lancellotti, Patrizio | Bax, Jeroen | Marwick, Thomas | Chioncel, Ovidiu | Jaarsma, Tiny | Mullens, Wilfried | Piepoli, Massimo | Thum, Thomas | Heymans, Stephane | Mueller, Christian | Moura, Brenda | Ruschitzka, Frank | Zamorano, Jose Luis | Rosano, Giuseppe | Coats, Andrew J.S. | Asteggiano, Riccardo | Seferovic, Petar | Edvardsen, Thor | Lyon, Alexander

Edité par CCSD ; European Society of Cardiology (Wiley) -

International audience. Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position statement examines the role of echocardiography, cardiac magnetic resonance, nuclear cardiac imaging and computed tomography in the management of cancer patients. The Imaging and Cardio-Oncology Study Groups of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the ESC have evaluated the current evidence for the value of modern CV imaging in the cardio-oncology field. The most relevant echocardiographic parameters, including global longitudinal strain and three-dimensional ejection fraction, are proposed. The protocol for baseline pre-treatment evaluation and specific surveillance algorithms or pathways for anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor tyrosine kinase inhibitors, BCr-Abl tyrosine kinase inhibitors, proteasome inhibitors and immune checkpoint inhibitors are presented. The indications for CV imaging after completion of oncology treatment are considered. The typical consequences of radiation therapy and the possibility of their identification in the long term are also summarized. Special populations are discussed including female survivors planning pregnancy, patients with carcinoid disease, patients with cardiac tumours and patients with right heart failure. Future directions and ongoing CV imaging research in cardio-oncology are discussed.

Consulter en ligne

Suggestions

Du même auteur

Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology

Archive ouverte | Pudil, Radek | CCSD

International audience. Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in cardiac...

Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association ( HFA ) of the European Society of Cardiology ( ESC )

Archive ouverte | Boer, Rudolf | CCSD

International audience. The co-occurrence of cancer and heart failure (HF) represents a significant clinical drawback as each disease interferes with the treatment of the other. In addition to shared risk factors, a...

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Archive ouverte | Lyon, Alexander | CCSD

International audience

Chargement des enrichissements...